Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Prostate cancer prognosis

The prognosis for prostate cancer patients depends on the histologic grade, the tumor size, and the disease stage. More than 85% of patients with stage Aj disease but less than 1% of those with stage D2 can be cured. [Pg.1357]

Alterations in the signal transduction pathways mediated by HER-2 play an important role in the progression of prostate cancer. This protein is normally expressed at a very low level in a few human secretory epithelial cells but is overexpressed in a number of human cancers, including prostate carcinoma. Overexpression of HER-2 is an indicator of poor prognosis in prostate cancer patients. [Pg.288]

In recent RT-PCR studies, many kallikreins have been proposed as new biomarkers for malignancies other than prostate cancer. Breast, ovarian, and testicular cancers are the most studied. Certain kallikreins were found to be differentially expressed in various malignancies (up- or downregulated), and the increase or decrease of their expression may be associated with prognosis [43, 58, 70, 89-94]. We have immunohistochemically evaluated some kallikreins in malignant diseases, including two series of prostate and renal cell carcinoma, and have examined their prognostic values [84, 85]. [Pg.30]

The association of kallikreins with cancer is well established. PSA (hK3) and, more recently, human glandular kallikrein (hK2) are useful biomarkers for prostate cancer. A more detailed discussion about hK2 and hK3 as cancer biomarkers can be found elsewhere [31]. In addition to its established role in prostate cancer diagnosis and monitoring, recent reports indicate that hK3 can be useful as a marker for breast cancer prognosis [215],... [Pg.53]

The widespread application of serum markers for cancer screening, like prostate-specific antigen (PSA) for prostate cancer and Carcino-Embryonic Antigen (CEA) for colon cancer, has led to the perception that specific and accurate markers, yet to be discovered, will be the answer to early diagnosis and prognosis. [Pg.524]

Miyake H, Hara I, Yamanaka K, Gohji K, Arakawa S, Kamidono S. Elevation of serum levels of urokinase-type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer. Prostate 1999 39(2) 123-129. [Pg.101]

D7. Daniell, H. W., A better prognosis for obese men with prostate cancer. J. Urol. 155, 220-225... [Pg.144]

K3. Kim, I. Y., Ahn, H. J., Lang, S., Oefelein, M. G., Oyasu, R., et al., Loss of expression of transforming growth factor-beta receptors is associated with poor prognosis in prostate cancer... [Pg.149]

Saramaki OR, Harjula AE, Martikainen PM, et al. TMPRSS2 ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis. Clin Cancer Res. 2008 14 3395. [Pg.653]

Akashi T, Koizumi K, Tsuneyama K, et al. (2008) Chemokine receptor CXCR4 expression and prognosis in patients with metastatic prostate cancer. Cancer Sci 99 539-542... [Pg.56]


See other pages where Prostate cancer prognosis is mentioned: [Pg.617]    [Pg.175]    [Pg.617]    [Pg.175]    [Pg.1360]    [Pg.1362]    [Pg.440]    [Pg.469]    [Pg.726]    [Pg.111]    [Pg.228]    [Pg.117]    [Pg.118]    [Pg.53]    [Pg.56]    [Pg.56]    [Pg.56]    [Pg.59]    [Pg.60]    [Pg.161]    [Pg.395]    [Pg.84]    [Pg.543]    [Pg.106]    [Pg.713]    [Pg.164]    [Pg.1810]    [Pg.419]    [Pg.756]    [Pg.760]    [Pg.786]    [Pg.26]    [Pg.2423]    [Pg.2428]    [Pg.605]    [Pg.618]    [Pg.1256]    [Pg.214]    [Pg.44]    [Pg.330]   
See also in sourсe #XX -- [ Pg.2428 ]




SEARCH



Cancer, prostat

PROGNOSYS

Prostate cancer

Prostatic cancer

© 2024 chempedia.info